Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 12/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26316625 | 0.84 | NOS2 (0.55) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL26316499 | 0.81 | NOS2 (0.59) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL26316623 | 0.79 | NOS2 (0.62) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL26316590 | 0.79 | NOS2 (0.56) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL26316626 | 0.75 | NOS2 (0.56) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL26316615 | 0.75 | NOS2 (0.53) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL6492468 | 0.74 | NOS2 (1.00) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL6490554 | 0.74 | NOS2 (1.00) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL26321134 | 0.74 | NOS2 (0.54) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| Hydrochloric Acid SCHEMBL6491456 | 0.73 | NOS2 (0.97) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286913-A1 | INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | Gacter Inc. (US) | 2023-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286913-A1 | INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | NOS1, NOS3, NOS2 | NOS2 3/4885CYP2D6 360/4885SLC6A2 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.